An unanswered question regarding Alzheimer disease dementia (ADD) is whether amyloid-beta (A) plaques sequester toxic soluble A species early in the pathological progression. We previously reported that the concentration of soluble A aggregates from patients with mild dementia was higher than soluble A aggregates from patients with modest A plaque burden but no dementia. The ratio of soluble A aggregate concentration to A plaque area fully distinguished these groups of patients. We hypothesized that initially plaques may serve as a reservoir or sink for toxic soluble A aggregates, sequestering them from other targets in the extracellular space and thereby preventing their toxicity. To initially test a generalized version of this hypothesis, we have performed binding assessments using biotinylated synthetic A 1-42 peptide. A 1-42 -biotin peptide was incubated on unfixed frozen sections from non-demented high plaque pathology controls and patients with dementia of the Alzheimer type. The bound peptide was measured using ELISA and confocal microscopy. We observed no quantitative difference in A binding between the groups using either method. Further testing of the buffering hypothesis using various forms of synthetic and human derived soluble A aggregates will be required to definitively address the role of plaque buffering as it relates to ADD.
Introduction
The relationship between A plaque pathology and Alzheimer disease dementia (ADD) (1) has been a topic of considerable controversy. Soluble A aggregates have been more directly linked to toxicity in vitro and in some animal model systems (2) . We recently reported that soluble A aggregates (termed "oligomers" in prior publications) were elevated in aqueous brain lysates from patients with early ADD in comparison with lysates from patients with A plaque 3 pathology but no dementia (3) . However, despite statistically significant differences, there was still considerable overlap between groups. In further analyses, we found that the ratio of soluble A aggregate levels to plaque area instead fully distinguished between patients with early ADD from patients with plaques but no dementia. This finding was replicated in a second cohort of cases. While it is likely that this finding indicates a fundamentally important pathophysiological linkage underlying ADD, the interpretation of the result is not straightforward. We posited in our initial report that plaques could serve as binding reservoirs or buffers for soluble A aggregates; at early stages, A plaques could adequately buffer soluble aggregates, protecting the nearby neuropil from toxicity, whereas at later times if buffering capacity was lost or overwhelmed, soluble aggregates could be free to diffuse in the extracellular space and exert toxicity (3) . Direct binding and unbinding of soluble aggregates to the plaques themselves would be the most straightforward mechanism, but binding and unbinding to peri-plaque elements including dystrophic neurites, microglia, and astrocytes would be functionally equivalent. This idea was also based in part on the observations of Koffie et al., who reported loss of synapses in a gradient around plaques both in transgenic mice (4) and human brain sections (5) , along with a halo of immunoreactivity consistent with soluble aggregates/oligomeric species; these results were interpreted as consistent with release of synaptotoxic soluble aggregates from plaques. Because synapse loss correlates strongly with dementia (6, 7) the failure of buffering leading to synaptic toxicity could be proposed as a substrate of dementia. The question of whether failure of buffering of soluble A by plaques underlies ADD leads to several non-mutual exclusive hypotheses (2): Hypothesis 1: Qualitative changes in the A plaques correlate with dementia severity; plaques from non-demented controls retain more buffering capacity than plaques from demented patients. Hypothesis 2: Qualitative changes in the soluble A aggregates correlate with dementia; soluble A aggregates from demented cases bind to A plaques less avidly than soluble A aggregates from non-demented controls. Here we report our first efforts towards testing Hypothesis 1. Specifically, we assessed A buffering capacity of plaques in frozen brain slices from non-demented controls vs. patients with early dementia. While we have made initial progress in purifying soluble A aggregates from human brain tissue (8), we have not yet achieved sufficient purification for to use native human brain aggregates for these buffering studies. Therefore, we used biotinylated synthetic A peptide for these initial experiments, reasoning that if plaque buffering of soluble A is a general property, that this approach could yield insight into the buffering properties.
Materials and Methods

Regulatory Compliance
All protocols were carried out in accordance with the Charles F. and Joanne Knight Alzheimer 5 Disease Research Center, Washington University guidelines. This specific study was approved by the Knight Alzheimer Disease Research Center. All donors or family members gave informed consent for a brain donation and use in research studies.
Selection and sectioning of human frontal cortical tissue
Clinically and neuropathologicaly well-characterized cases were obtained from the Unfixed frontal cortex was embedded in 'optimum cutting temperature' (O.C.T., Sakura
Finetek, USA) compound and frozen by immersion in liquid nitrogen chilled 2-methylbutane.
The tissue blocks were then equilibrated at -20°C and 18µm sections were cut and mounted directly onto positively charged glass slides using a Leica CM 1950 cryostat. The tissue sections were stored at -80°C prior to use. 
Immunohistochemical staining of human cortical tissue
Free-floating 50µm tissues sections were washed 3x in Tris-buffered saline (TBS) for 5 minutes each and then incubated with 0.3% H 2 O 2 in TBS for 10 minutes at room temperature to block endogenous peroxidase. Following the incubation, sections were rinsed in TBS 3x for 5 minutes each, and then blocked with 5% normal goat serum (NGS) in TBS containing 0.25% (v/v) Triton X100 for 30 minutes at room temperature. Sections were then incubated with the A-specific Nterminal mouse monoclonal HJ3.4 in 1% NGS in TBS-X at a 1:1000 dilution overnight at 4°C.
The following day, sections were washed 3x in TBS for 5 minutes each and incubated with a biotinylated secondary goat anti-mouse antibody at a 1:1000 dilution in TBS-X for 1 hour at room temperature (Vector Laboratories). Following the incubation of the secondary antibody, the sections were washed 3x in TBS for 5 minutes each, incubated with ABC Elite (Vector Laboratories) at a 1:400 dilution in TBS for 1 hour at room temperature, then washed with TBS 3x for 5 minutes and developed with 3,3'-diaminobenzidine (#D5905; Sigma-Aldrich). Sections were mounted and dehydrated using a standard ethanol-xylene series followed by coverslipping.
For each patient, three tissue sections separated by 600µm were stained for analysis.
Quantification of immunohistochemical staining with ImageJ
Immunohistochemical samples from each patient were scanned using a Hamamatsu NanoZoomer HR model (Hamamatsu, Bridgewater, NJ). The percentage of gray matter containing HJ3.4 immunopositive A plaque was measured using the Analyze Particles ImageJ (NIH) plug-in on thresholded 8-bit images with user defined gray-matter distinct regions of interest. The image thresholding was performed equally across the full sample set. During 7 quantitation, the samples were coded such that the user was masked to the patient ID and CDR status. and incubated for 18 hours at room temperature in a humidified chamber. Following overnight binding, the tissue sections were gently washed 3x for 5 minutes each with binding buffer at room temperature. For direct quantification of the bound biointylated A 1-42 the tissue was dissociated using concentrated formic acid (n=3 sections/patient) and aliquoted into sterile microcentrifuge tubes. The formic acid in each sample aliquot was removed by vacuum centrifugation and the samples stored at -80°C until assayed. For confocal microscopy, the remaining sections (n=3/patient) were fixed with 4% paraformaldehyde in chilled methanol.
Binding of A 1-42 -biotin to unfixed frozen human cortical tissue
Assessment of ex-vivo binding of A 1-42 -biotin by confocal microscopy
The A 1-42 -biotin bound then paraformaldehyde-fixed cortical tissue sections (n=3/patient) were subjected to signal amplification to allow for confocal image acquisition. The fixed sections 8 were washed 3x in aCSF for 5 minutes each and incubated with ABC Elite at a 1:400 dilution in aCSF for 1 hour at room temperature. The signal was then amplified using the Biotin-XX Tyramide SuperBoost Kit (B40931, Thermo Fisher Scientific) with a development time of 10 minutes followed by washing 3x in aCSF for 5 minutes each. To quench endogenous autofluorescence the tissue sections were treated with TrueBlack (23007, Biotium, Fremont, CA) for 2 minutes followed by extensive washing in aCSF to remove residual reagent. The quenched, amplified sections were then incubated with streptavidin Alexa Fluor™ 594 conjugate (S11227, Thermo Fisher Scientific) at 1:1000 diluted in 0.1% BSA in aCSF for 30 minutes. The sections were washed 3x in aCSF for 5 minutes each, followed by counterstain with 4′,6diamidino-2-phenylindole (DAPI , Sigma-Aldrich), and a final wash series before mounting with ProLong Gold Antifade media (P10144, Thermo Fisher Scientific). Images were acquired using an Olympus FV1200 scanning confocal microscope equipped with gallium arsenide phosphide detectors. Tiled (4x5), 7.5 micron z-stack images were acquired using a UPLFLN 20x (NA:0.70) objective with a laser output (0.5%) that produced non-saturated pixel data. All patient sections were acquired using the same instrument settings.
Quantification of confocal imaging with ImageJ
Confocal acquired tiled images files (Olympus .OIB format) from each patient were imported into ImageJ for analysis. Using the DAPI channel, a global region of interest was defined to exclude non-tissue area. The Alexa Fluor™ 594 channel was converted to a z-projection using the "sum of slices" setting. A duplication of the z-projection was converted to an 8-bit image and used to create a threshold overlay mask within the Analyze Particles plugin. The overlay masks were imported into the ROI manager. The original z-projection was converted to an 8-bit image and the global ROI was used to deselect any overlay mask outliers. The global ROI and 9 the overlay masks were used to measure the integrated density and area measures for each image.
An additional measurement was made in the non-Alexa Fluor™ 594 region to serve as a background subtraction control. The image thresholding was performed equally across the full sample set. During quantitation, the samples were coded such that the user was masked to the patient ID and CDR status.
Measurement of A 1-42 biotin by ELISA
Measurement of the formic acid soluble recovered N-terminally biotinylated A 1-42 was determined by ELISA using the mid-domain binding antibody HJ5.1 to capture and polystreptavidin HRP-20 to detect bound peptide. HJ5.1 was coated to 96-well Nunc Maxisorp plates at 20 μ g/mL in carbonate buffer (35 mM sodium bicarbonate, 16 mM sodium carbonate, 3 mM sodium azide, pH 9.6) in 100 μl/well overnight at 4°C. Plates were washed 5x between steps with PBS using a BioTek EXL405 plate washer. The assay plates were blocked using 0.2 μm filtered 4% BSA in PBS for 1 hour at room temperature. Samples and standard were diluted in standard diluent, as described above, to a 100μL volume and loaded. An 8-point standard curve was generated using 5000, 1666.7, 555.6, 185.2, 61.7, 20.6, and 6.9 pg/mL of the N-terminal biotinylated synthetic A 1-42 loaded in triplicate. All samples were kept on ice during handling and the assay plates were incubated at 4°C overnight prior to development.
Measurement of total A 1-x by ELISA
The quantification of the A 1-x isoforms was performed as previously described (8) . The samples were resuspended in 5M guanidine-HCl prior to dilution with standard buffer (0.2 μm filtered 0.25% BSA, 0.5 M guanidine-HCl, 0.005% Tween-20, 300 mM Tris, 3 mM sodium azide, 2 μg/mL aprotinin, 1 μ g/mL leupeptin, in PBS). The samples were loaded onto HJ5.1 coated 96-well Nunc Maxisorp plates, which were blocked with 4% BSA, in addition to synthetic A 1-40 monomer standard loaded in triplicate. Following overnight incubation, the assay plates were detected using biotinylated HJ3.4 which binds N-terminally intact A but should not bind to N-terminally biotinylated A . The assay was developed as previously described using poly-streptavidin HRP-20 (65R-S103PHRP, Fitzgerald, Acton, MA) and addition of 3,3',5,5'-tetramethylbenzidine (T5569, Sigma-Aldrich) with the absorbance read on a
BioTek Synergy 2 plate reader at 650 nm.
Total protein quantification
Total protein was quantified in the formic acid dissociated samples using a fluorescence-based 96-well NanoOrange assay (N6666, Thermo Fisher Scientific). Sample aliquots were resuspended in 4M urea as well as dilutions of the reference BSA standard to normalize for effect on the assay. Appropriate dilutions for each samples and the standard were combined with assay reagent in a 96-well black microplate and measured by excitation at 485nm and emission at 590nm using a BioTek Synergy 2 plate reader.
Assessment of A 1-42 -biotin during binding by size-exclusion chromatography
To determine if qualitative size changes or quantitative loss of A 1-42 -biotin occurred during the room-temperature overnight incubation period, we assessed pre-and post-incubation samples by size-exclusion chromatography. Clean slides without tissue were prepared and blocked the same as for the tissue sections. The blocking solution was replaced with 150µl binding buffer (0.05% BSA in aCSF) containing 10nM N-terminal biotinylated synthetic A 1-42 and incubated for 18 hours at room temperature in a humidified chamber. For the pre-incubation sample, the peptide solution was immediately recovered into a blocked-microcentrifuge tube. The recovered sample was injected onto a pre-equilibrated Superdex 200 10/300 GL column pre-equilibrated with 0.05% BSA in aCSF. The sample was eluted at 0.5 ml/min at 4°C and then immediately diluted 11 and loaded onto an ELISA plate coated with HJ5.1 for quantitative analysis. The overnight incubation sample was recovered and assessed by size-exclusion chromatography in the same manner.
Results
Plaque coverage and morphology was indistinguishable between nondemented controls vs. patients with early ADD.
As demonstrated in our previous report(3), A plaques immunoreactive with the A N-terminal specific antibody HJ3.4 covered similar portions of the gray matter in non-demented controls compared to patients with early ADD (Fig. 1) . The brain samples used in these experiments came from different cases than those used for our previous report, but the demographics of the patients and the characteristics of the  plaque pathologies were very similar ( Table 1) . (G) Gray matter coverage by A plaque pathology was not different in the nondemented elderly subjects with plaques (CDR 0 + plaques) versus subjects with mild ADD (CDR 1) type (not significant [n.s.] by Mann-Whitney U test).
No difference between binding of biotinylated A 1-42 bound to plaques in nondemented controls vs. plaques in patients with early ADD: results from confocal imaging.
After binding of soluble biotinylated A 1-42 for 18 hours at room temperature to frozen sections followed by gentle washing in binding buffer (0.05% BSA in aCSF), biotinylated A 1-42 was retained in structures similar in size and morphology to A plaques and did not appear to non-13 specifically bind throughout the tissue (Fig 2A, B, D-F) . No binding was detected in brain sections from patients without plaques (Fig 2C) , or on blank slides. Binding of biotinylated A 1-42 covered 0.407+/-0.124% of the brain area in slices from non-demented controls and 0.433+/-0.089% of the area in slices from patients with early dementia. The area covered did not differ between groups (Fig 3A¸ p=0.6299) . The area covered by bound soluble biotinylated A 1-42 did not correlate with the total immunohistochemically detected plaque coverage (Fig 3B) . The total fluorescence intensity also did not differ between groups (p=0.9463). After normalization by total A plaque area, total fluorescence intensity similarly did not differ between groups (Fig   3C) . Thus, the binding capacity of plaques for synthetic biotinylated A does not appear to differentiate demented from non-demented high plaque control brains. 
No difference between binding of biotinylated A 1-42 bound to slices from nondemented controls vs. slices from patients with early ADD: results from ELISA
Confocal imaging is most sensitive to tightly localized fluorescence, such as that due to binding of A to discrete plaques and peri-plaque structures. However, it is also possible that other brain tissues could bind and buffer A more diffusely, which might be difficult to detect using confocal microscopy. Therefore, we also used a parallel biochemical approach in which we incubated separate sets of frozen brain slices from the same patients with biotinylated A 1-42 , washed, and then lysed the slices in formic acid to solubilize all of the A in the slices for measurement by ELISA. In agreement with the previous results, we found no difference between the biotinylated A 1-42 in the lysates from slices from non-demented controls vs. slices from patients with early ADD (Fig 4A, p=0.0559 ). There were no differences between groups after normalizing by total A 1-x in the lysates (Fig 4B, p=0.7925 ), nor after normalizing by A plaque coverage (Fig 4C, p=0.0934 ). Thus, an orthogonal approach to measurement of buffering capacity similarly did not differentiate demented from non-demented patients. 
Synthetic A 1-42 is partially aggregated at baseline and aggregates further over time during the binding experiments.
Synthetic A 1-42 can be induced to form a large number of aggregation forms, from dimers to higher order oligomers. We performed size exclusion chromatography under neutral pH conditions to examine the size forms of the synthetic A in the solutions that were applied to the slices, and again to examine the size forms present in the supernatant from the slices after the 18 hour incubation on slices at room temperature. At baseline, most of the A 1-42 appeared monomeric, running in fractions 18 to 22 between the 17kDa and 1.35kDa size standards (Fig 5 black solid circles). A small portion appeared to be high molecular weight running in fractions 8 to 9 equivalent to the 670kDa size standards. After incubation, the A was still mainly monomeric, but a portion had shifted to slightly larger appearing forms, in fractions 16 to 18 between the 44kDa and 17kDa size standards (Fig 5red 
Discussion
In summary, synthetic biotinylated A 1-42 binds to plaque-like structures indistinguishably in frozen brain slices from demented vs. non-demented high A plaque pathology donors. This negative result does not support the hypothesis that a generalizable differential buffering of A 19 by plaques underlies the difference between demented and non-demented high plaque pathology patients. However, appropriate methods to definitively address the plaque buffering hypothesis
have not yet been developed. Most importantly, native soluble A aggregates may have very different properties from synthetic biotinylated A 1-42 due to differences in proteoforms (9) , aggregation states, and potentially associated proteins (2) .
Relationship to Previous Studies
From a methodological perspective, our approach has similarities to those used previously by others. For example, Guo et al. (10) demonstrated that exogenously applied fluorescently labelled A 1-42 bound plaques in unfixed frozen human cortical sections, though their binding assays were performed for 30 minutes at 37°C rather than over 18 hours at room temperature as in our studies. Esler et al. (11) reported that synthetic A exposed to human cortical sections for a short time unbound quickly upon washing, whereas synthetic A exposed for longer times unbound at substantially slower rate. These results, and others, led to the two process 'dock-lock' model of soluble A interacting with plaques. We specifically used an 18 hour binding time to attempt to assess both processes in our studies. Tseng et al. (12) reported that while monomeric A bound plaques from AD brain, aged high molecular weight synthetic A aggregates did not show detectible plaque binding. Concordantly, the majority of the A in our experiments was monomeric throughout the experiment, though there appeared to be some aggregation over time.
However, none of these previous investigations compared A binding to slices from brains of patients with dementia vs. from patients with indistinguishable plaque burden but no dementia.
The above discussed studies involved binding to ex vivo human brain tissue plaques, whereas other groups have investigated similar properties in living animal models. For example, 
Limitations and Future Directions
The main limitation of our approach was that we used synthetic monomeric A. Future studies will be required to assess the properties of human brain-derived A monomers and soluble A aggregates. Importantly, the characteristics of native human brain-derived A may not be comparable to those of synthetic A aggregates due to the wide variety of proteoforms, aggregation states, and potentially co-associated proteins. For example, Jin et al. (14) demonstrated that synthetic A dimers are orders of magnitude less biologically active than human brain-derived A immunoreactive species of comparable apparent size. Similarly, Noguchi et al (15) reported that native human brain high molecular mass A aggregates were substantially more toxic than similar size synthetic A aggregates.
The ability to label A aggregates extracted and purified from the human brain without disrupting their native tertiary structure will be essential for these future endeavors. Having methods to compare the initial state and the labelled state will be important to ensure that experiments can be interpreted accurately. We envision testing for whether the process of labeling native brain A aggregates disrupts their properties by using a competition assay; for example if the directly measured affinity of labeled native brain A is similar to the inferred affinity of unlabeled native brain A as a competitor, this would be reassuring.
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Ongoing work in our group and that of others should soon begin to address hypothesis 2 above by directly determining the A proteoform composition of soluble A aggregates extracted from the brains of patients with dementia vs. patients with indistinguishable plaque burden but no dementia. From there, the ability of plaques to buffer soluble A aggregates from the two patient sources or synthetic versions of differentially abundant proteoforms will be tested directly.
A second limitation involves the use of frozen ex vivo brain slices. If active cellular processes play a role in the functional buffering of A, this would not be detectible in our assays.
In theory, microdose PET tracer labeled A could be infused into local regions in the brains of patients undergoing other clinically indicated neurosurgical procedures such as shunting for normal pressure hydrocephalus. Retention vs. clearance of the PET tracer label could be then compared between non-demented low plaque, non-demented high plaque, and demented high plaque individuals.
A third limitation is that we did not measure the full kinetic binding properties of the A in our experiments, nor did we measure binding at physiological temperature. It is possible that differences between the two groups in the kinetics of A binding could be important, even though the likely near-equilibrium binding we measured did not differ between groups.
Implications
A more complete understanding of the differences between the A found in the brains of patients with dementia vs. patients with equivalent presence of plaque burden but no dementia may be key to developing A-targeted therapeutics for ADD. It is quite possible that despite many years and many clinical trials, the appropriate A therapeutic targets most relevant to dementia still have not been identified.
